Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention

D. Wiviott, Stephen; Trenk, Dietmar; L. Frelinger, Andrew; L. O’Donoghue, Michelle; Neumann, Franz‐Josef; D. Michelson, Alan; J. Angiolillo, Dominick; Hod, Hanoch; Montalescot, Gilles; L. Miller, Debra; A. Jakubowski, Joseph; Cairns, Richard; A. Murphy, Sabina; H. McCabe, Carolyn; M. Antman, Elliott; Braunwald, Eugene

doi:10.1161/circulationaha.107.740324

Public

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention

Published in Circulation • Dec 4, 2007

Authors:

Stephen D. Wiviott

Dietmar Trenk

Andrew L. Frelinger

Abstract

BACKGROUND: The increasing use of higher-than-approved doses of clopidogrel in clinical practice is based in part on the desire for greater levels of inhibition of platelet aggregation (IPA). Prasugrel is a new thienopyridine that is more potent than standard-dose clopidogrel in healthy subjects and...

Subject

Medicine

Prasugrel

Clopidogrel

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!